Table 2.
Chemokine receptor expression on CD3+ and CD45RO+/CD4+† T-cells in peripheral blood and CSF
| CCR1 Median (range) | CCR2 Median (range) | CCR3 Median (range) | CCR5 Median (range) | CCR6 Median (range) | CXCR3 Median (range) | ||
|---|---|---|---|---|---|---|---|
| CD3+ | |||||||
| MS | Blood (%) | 0·9 (0·5–1·1) | 13·7 (7·3–27·9)*† | 7·4 (7·1–18·4) | 34·5 (20·8–49·6)*† | 29·6 (15·8–49·0) | 44·4 (32·3–58·6)*†† |
| CSF (%) | 0·7 (0·5–1·1) | 3·0 (1·1–4·8) | 0·8 (0·8–2·5) | 55·9 (48·4–62·8) | 26·4 (17·3–51·2) | 91·2 (88·2–93·1) | |
| No· exam· | 4 | 5 | 3 | 5 | 9 | 5 | |
| NIND | Blood (%) | 1·1 (0·5–2·1) | 17·2 (10·7–26·0)*† | 2·8 (0–18·8) | 36·6 (29·3–53·4)*† | 29·5 (22·8–49·1) | 51·2 (34·1–62·6)*†† |
| CSF (%) | 2·3 (1·2–4·5) | 2·7 (1·1–3·7) | 1·2 (0–4·2) | 63·6 (26·5–78·7) | 31·1 (17·7–50·2) | 91·9 (86·0–97·1) | |
| No· exam· | 7 | 6 | 4 | 14 | 14 | 11 | |
| CD45RO+/CD4+ | |||||||
| MS | Blood (%) | n·d· | n·d· | n·d· | 43·8 (26·6–69·00) | n·d· | 66·4 (61·4–71·8)**†† |
| CSF (%) | 38·1 (24·0–68·3) | 89·8 (86·2–94·7) | |||||
| No· exam· | 9 | 3 | |||||
| NIND | Blood (%) | n·d· | 31·4 (22·5–47·4)** | n·d· | 51·8 (30·7–70·5) | 56·9 (43·7–67·1)** | 61·0 (44·8–72·1)**†† |
| CSF (%) | 16·4 (8·2–30·3) | 52·2 (26·0–74·4) | 39·0 (32·2–54·5) | 90·3 (80·4–95·4) | |||
| No. exam. | 8 | 12 | 8 | 6 | |||
†
Since preliminary studies showed that >95% of all CD4+ T-cells in the CSF were CD45RO+, this marker was omitted in CSF stainings in order to optimally use the few cells available
††
P-values calculated on all patients as one group
*
P < 0·001
**
P < 0·01, blood versus CSF; MS, patients with inflammatory CNS demyelination {manifested as MS (21 patients), a clinically isolated syndrome suggestive of MS (10 patients), or recurrent multicentric myelitis (one patient); NIND, non-inflammatory neurological diseases.